ICU Medical, Inc. (NASDAQ: ICUI) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $4.4B. The Maz Rating grades it against the other companies in its sector.
ICU Medical, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $176.91, ICU Medical, Inc. trades at 74.3x trailing earnings, 2.1x sales and 2.0x book value, with an EV/EBITDA of 18.5. Over the last twelve months it generated about $2.2B of revenue and $60M of net income. It runs a gross margin of 38.7%, an operating margin of 6.8% and a net margin of 2.8%. It shows return on equity of 2.8%, return on invested capital of 4.3% and a free cash flow yield of 4.7%. On the balance sheet: a debt-to-equity ratio of 0.53 and a current ratio of 2.37. Over the past 52 weeks the share price ranged from $113.37 to $192.85, with a beta of 0.76.
ICU Medical, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 1 Strong Buy, 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, ICU Medical, Inc. (ICUI) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 27.5% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.3% / 30% · Interest income / Revenue 0.51% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 27.5% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.22% / 33% · Receivables / Mkt Cap (36m) 4.93% / 49% · Interest income / Revenue 0.51% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 27.5% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.22% / 33.33% · Receivables / Mkt Cap (24m) 4.93% / 33.33% · Interest income / Revenue 0.51% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 31.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.49% / 33.33% · Receivables / Avg Assets (4Q) 5.05% / 33.33% · Interest income / Revenue 0.51% / 5% | Pass |
| FTSE | Debt / Total Assets 29.2% / 33.33% · (Cash+ST Inv) / Total Assets 7.65% / 33.33% · (Cash+Recv) / Total Assets 12.9% / 33.33% · Interest income / Revenue 0.51% / 5% | Pass |
Yes. As of September 2026, ICU Medical, Inc. (ICUI) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. ICU Medical, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.51% of each dividend: ICU Medical, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.